– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) – – NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – WALTHAM, Mass., Aug. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMEN ...

Kennametal Inc. (KMT) reported fourth-quarter fiscal 2024 (ended Jun 30, 2024) adjusted earnings of 49 cents per share, which beat the Zacks Consensus Estimate of 44 cents. The bottom line decreased 3.9% from the yearago figure. Revenue Details Kennametal's revenues were $543 million, which decreased 1% from the year-ago quarter's figure. Organic sales declined 1% year over year. Business days had a positive impact of 2%. Currency exchange negatively impacted sales by 2%. KMT's revenues beat the Zacks Conse ...

FY24 Fourth Quarter Earnings Call Presentation August 7, 2024 Q4 FY24 EARNINGS Safe Harbor Statement Certain statements in this release may be forward-looking in nature, or "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements that do not relate strictly to historical or current facts. For example, statements about Kennametal's outlook for sales, adjusted operating income, ...

For the quarter ended June 2024, Kennametal (KMT) reported revenue of $543.31 million, down 1.3% over the same period last year. EPS came in at $0.49, compared to $0.51 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $532.09 million, representing a surprise of +2.11%. The company delivered an EPS surprise of +11.36%, with the consensus EPS estimate being $0.44. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Kennametal (KMT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.36%. A quarter ago, it was expected that this engineered products maker would post earnings of $0.31 per share when it actually produced earnings of $0.30, delivering a surprise of -3.23%. Over the last four quarters, ...

Q4 earnings per diluted share (EPS) of $0.47 compared to $0.45 in the prior year quarter FY24 EPS of $1.37 and adjusted EPS of $1.50 Strong YTD cash from operations of $277 million compared to $258 million in the prior year; highest as a percent of sales in over 25 years Returned $129 million to shareholders in FY24; $65.4 million in share repurchases and $63.4 million in dividends Completed initial three-year $200 million share repurchase program; previously announced $200 million program in place for FY25 ...

PITTSBURGH, Aug. 5, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced that David Bersaglini will join the company as Vice President of Kennametal Inc. and President of the Metal Cutting segment, effective August 26, 2024. Bersaglini has nearly 25 years of experience and comes to the company from Copeland, a spin-off of Emerson, where he was Vice President and General Manager of Global Refrigeration. "Dave brings a strong track record of success to Kennametal, with extensive experience leading ...

Core Points - The FDA has extended the PDUFA action date for revumenib to December 26, 2024, allowing additional time for review [1][3][8] - Revumenib is positioned to be the first drug approved for treating KMT2A-rearranged acute leukemia, addressing a significant unmet medical need [1][10] - The drug has received multiple designations from the FDA, including Breakthrough Therapy, Fast Track, and Orphan Drug designations [9][10] Company Overview - Syndax Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative cancer therapies [8][10] - The company's pipeline includes revumenib, a selective inhibitor targeting the menin-KMT2A binding interaction, and axatilimab, a monoclonal antibody [5][10] Regulatory Process - Revumenib's NDA is under the FDA's Real-Time Oncology Review (RTOR) program, which facilitates a more efficient review process for oncology drugs [9][5] - The FDA's request for additional information constituted a Major Amendment to the NDA, resulting in a standard three-month extension [3][8]

Details of the conference call and webcast are as follows: With over 80 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions. Customers across aerospace and defense, earthworks, energy, general engineering and transportation turn to Kennametal to help them manufacture with precision and efficiency. Every day approximately 8,700 employees are helping customers in nearly 100 countries stay competitive. Kenn ...

Discover innovative tooling solutions, machining demonstrations, giveaways and more at the Kennametal booth "Our Metal Cutting Tour has been wildly successful in engaging with our customers. We're building on this success by bringing the same experience to IMTS with Metal Mania," said Eddie McBarnet, Vice President of Commercial & Marketing, Kennametal. "Attendees can meet with our team of likeminded creators and experts, connect with well-known industry machinists, be the first to discover exclusive new to ...